Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL ...
Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel ( Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA )
16 Dec 2020
Researchers trace the origin of blood cancer to early childhood, decades before ...
Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK
Researchers trace the origin of blood cancer to early childhood, decades before diagnosis ( Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK )
16 Dec 2020
Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by ...
Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA
Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by measuring circulating tumour DNA ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )
15 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
ASH 2020:  Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )
15 Dec 2020
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...
Dr Francesca Gay - University of Torino, Torino, Italy
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
14 Dec 2020
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )
11 Dec 2020
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
10 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
10 Dec 2020